WO1996004906A1 - Compounds for the treatment of restenosis - Google Patents
Compounds for the treatment of restenosis Download PDFInfo
- Publication number
- WO1996004906A1 WO1996004906A1 PCT/GB1995/001899 GB9501899W WO9604906A1 WO 1996004906 A1 WO1996004906 A1 WO 1996004906A1 GB 9501899 W GB9501899 W GB 9501899W WO 9604906 A1 WO9604906 A1 WO 9604906A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dione
- carbazole
- defined above
- pyrrolo
- indolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is concerned with compounds of formula (I) having use in the prophylaxis or treatment of restenosis. In particular, the invention relates to the use of these compounds in the manufacture of medicaments for the prophylaxis or treatment of restenosis, to medicaments obtained thereby, and to a method for treatment to prevent or alleviate restenosis using the compounds of the invention or a medicament containing said compounds.
Description
C0MP0UNDS FOR THE TREATMENT OF RESTENOSIS
The present invention is concerned with compounds having use in the prophylaxis or treatment of restenosis. In particular, the invention relates to the use of these compounds in the manufacture of medicaments for the prophylaxis or treatment of restenosis, to medicaments obtained thereby, and to a method for treatment to prevent or alleviate restenosis using the compounds ofthe invention or a medicament containing said compounds.
Restenosis can occur following a number of surgical techniques, for example, transplant surgery, vein grafting, coronary by-pass grafting and, most commonly, following angioplasty.
Angioplasty is a surgical technique wherein atherosclerotic stenoses in the peripheral, renal and coronary vasculature are opened up by compressing and/or tearing the plaque on the vessel walls, typically by means of a pressurised balloon catheter. Unfortunately, in 25 to 50 % of cases, particularly those involving the coronary vasculature, the treated vessel restenoses within a few months so that the operation must be repeated. Alternatives to the balloon catheter, such as pulsed lasers and rotary cutters, have been developed with a view to reducing or preventing restenosis following angioplasty, but have met with limited success. A number of drugs including anti-coagulants and vasodilators have also been tried with disappointing or equivocal results.
There is now a strong body of evidence, from work done both in vitro and in vivo, indicating that restenosis is a multifactorial process. Several cytokines and growth factors, acting in concert, stimulate the migration and proliferation of vascular smooth muscle cells (SMC) and production of extracellular matrix material, which accumulate to occlude the blood vessel. One growth factor in particular, platelet-derived growth factor (PDGF), is a potent mediator of SMC proliferation and migration.
Several observations place PDGF in a central role in the restenosis process and suggest that an inhibitor of PDGF action would be therapeutically useful. One approach to blocking PDGF action is to inhibit at the level ofthe PDGF receptor. It is now clearly established that the intrinsic tyrosine kinase activity ofthe PDGF receptor is absolutely required for PDGF-dependent SMC proliferation and migration. Therefore, inhibiting
PDGF receptor tyrosine kinase activity would be expected to block the biological effects of PDGF and reduce the extent of restenosis.
We have now identified a class of compounds which are inhibitors of the platelet- derived growth factor receptor (PDGFr) tyrosine kinase.
Patent applications WO 93/18766 and WO 95/07910 disclose indole derivatives and their use in medical therapy. It is these compounds which we have now found to be useful in the prophylaxis or treatment of restenosis.
According to the present invention, there is provided use of compounds of formula (I)
wherein:
R.1 and R^ are independently selected from:
-H,
-OR6, -COR6, -CO2R6, where R6 is Cj_6 alkyl, C3.7 cycloalkyl, aryl (for example phenyl), arylalkyl (for example benzyl), C2-6 alkenyl, or H,
- R7R8 where R7 and R are independently selected from H, -COR6 (where R6 is as defined above),
C3_7cycloalkyl, aryl, and arylalkyl, or R7 and R** together with the N atom to which they are attached form a 3-, 4-, 5- or 6- membered heterocyclic ring (for example piperidine, pyrrolidine) in which from
1 to 3 ofthe carbon atoms are replaced by heteroatoms independently selected from O, N and S (for example, morpholino, piperazine) which ring may where possible be partially or completely unsaturated, and
-Cι_4alkyl, C2-4alkenyl, C3_gcycloalkyl, where the alkyl, alkenyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from: halogen, cyano, nitro, azido,
-OR6, -SR6, -SO2R6 (where R6 is as defined above),
-NR7R8, -T-C(Z)-NR7R8 (where T is NH or S, Z is NH, S or O and R7and
R8 are as defined above), heterocycle, -NH-heterocycle, heteroaryl, and aryl (for example phenyl, pyridyl, furyL, thienyl, pyrrole, naphthyl) optionally substituted by one or more substituents selected from -OR6, -NR7R8, -SR6, -SO2R6, -CO2R6, nitro, cyano, SCN, C^galkyl, C3_6cycloalkyl, haloalkyl (for example trifluoromethyl), hydroxylalkyl, -CONH2, halogen and methylenedioxy, (where
R6,R7, and R8 are each as defined above);
R3 is selected from:
-H,
-COR6, -CH2OR6, -CO2R6, -OR6 (where R6 is as defined above),
-NR7R8, and -CH2 R7R8 (where R7 and R8 are as defined above);
R4 and R-> either together with the carbon atom to which they are attached form a carbonyl group (>=O) or R4 is H and R5 is selected from H, -OR6,and -SR6, (where R6 is as defined above);
A and B, which may be the same or different, together with the carbon atoms to which they are attached each represent a phenyl ring in which from 1 to 3 carbon atom(s) may be replaced by nitrogen atom(s), the nitrogen atom(s) being optionally substituted with an oxide group;
A and B are optionally substituted by one or more ring substituent(s) selected from:
-Ci.Qa&yl optionally substituted by -OR6 (where R6 is as defined above), halogen (for example trifluoromethyl), or -NR7R8 (where R7 and R8 are as defined above),
cyano, nitro, halogen, methylenedioxy,
-OR6, -SR6, -SOR6, -SO2R6, -CO2R6 -NHCOR6 (where R6 is as defined above),
-SO2NR7R8, -NHSO2R8, -CONR7R8, and - R7R8 (where R7 and R8 are as defined above);
provided that when A and B together with the carbon atoms to which they are attached both represent a phenyl ring R3 is not -CH2OR6 or -CH2N 7R8 and rings A and B are not substituted by -NHCOR6, (where R6, R7, and R8 are as defined above);
or a physiologically functional derivative thereof or a solvate of any thereof for use in the manufacture of a medicament for the treatment or prophylaxis of restenosis.
Preferred compounds of formula (I) are as defined above wherein R3 is hydrogen and R4 and Bβ together with the carbon atom to which they are attached foπn a carbonyl group; or a physiologically functional derivative thereof or a solvate of any thereof.
Further preferred compounds of formula (I) are as defined above wherein ring A and B together with the carbon atoms to which they are attached both represent a phenyl ring or one of A and B represents a phenyl ring and the other represents a pyridyl ring fused at the 2- and 3- positions; or a physiologically functional derivative thereof or a solvate of any thereof.
Preferred compounds of formula (I) include:
(i) 12-(2,3-D droxy-l-propyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione;
(ii) 12, 13-Dihydro-3,9-dimethoxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione;
(iii) 12, 13-Dihydro-3,9-dihydroxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione;
(iv) 13-Ethyl-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3)4-c]carbazole-5,7(6H)- dione;
(v) 12-(3-Aminopropyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione;
(vi) πH-π-EthylpyridoP'^'^^lpyrroloP^-alpyrroloP^-clcarbazole-SJfrH)- dione;
(vii) 12, 13-Dihydro-pyrido[2,,3':2,3]pyrrolo[3,4-c]carbazole-5,7(6H)-dione; and
(vϋi) 12-(3-Propanamide)- 12, 13 -dihydro-5H-indolo [2, 3 -a]pyrrolo [3 ,4-c]carbazole- 5,7(6H)-dione;
and physiologically functional derivatives thereof and solvates of any thereof.
Certain compounds of formula (I) as defined above are new compounds and represent a further feature of the present invention collectively as compounds of formula (IA) wherein:
R1 is H and R2 is:
-C2-4alkyl optionally substituted by one or more substituents selected from: -OR6', halogen, cyano, and -NR7^8', where R6' is Chalky., C2_6a*U∞nyl, or H, where R7' is H and R8' is Chalky!;
R3 is H
R4 and R^ together with the carbon atom to which they are attached form a carbonyl group (>=O);
A and B together with the carbon atoms to which they are attached each represent a phenyl ring optionally substituted by one or more ring substituent(s) selected from:
-OR6', -CO2R6' (where R6' is as defined above), cyano, nitro,
-C^alkyl optionally substituted with -OR6 (where R6' is as defined above), and
-NR7"R8" where R7" and R8 are independently selected from H and
provided that when A and B are both unsubstituted phenyl rings R2 is not ethyl or 2,3- dihydroxypropyl;
or a physiologically functional derivative thereof or a solvate of any thereof.
Preferred compounds of formula (IA) are as defined above where at least one of the phenyl rings A and B is substituted by one or more substituents as defined above.
Further preferred compounds of formula (IA) are as defined above where ring A is substituted at either position 2 or 3, or both, and/or ring B is substituted at either position 9 or 10, or both.
The exact position of substituents on ring A and B defined above can be determined by reference to the illustrative structure given below.
(i) 12-Ethyl- 12, 13-dihydro- 10-amino-5H-indolo[2,3 a]pyrτolo[3 ,4c]carbazole- 5,7(6H)-dione;
(ii) 12-Ethyl- 12, 13-dihydro- 10-carboxy-5H-indolo [2, 3 a]pyrrolo[3 ,4c]carbazole- 5,7(6H)-dione;
(iϋ) 12-Propyl-12, 13-dihydro-5H-indolo[2,3a]pyrrolo[3,4c]carbazole-5,7(6H)- dione;
(iv) 12-(2,2,2-Trifluoroethyl)-12,13-dihydro-5H-indolo[2,3a]pyrrolo[3,4c] carbazole-5, 7(6H)-dione;
(v) 12-(3-Hydroxypropyl)-12, 13-dihydro-5H-indolo[2,3a]pyrrolo[3,4c] carbazole-5,7(6H)-dione;
(vi) 12-(2,3-Dihydroxybutyl)-12, 13-dihydro-5H-indolo[2,3a]pyrrolo[3,4c] carbazole-5,7(6H)-dione; and
(vii) 12-(13-Acetoxypropyl)12,13-dihydro-5H-mdolo[2,3a]pyrrolo[3,4c]carbazole- 5,7(6H)-dione;
and physiologically functional derivatives thereof and solvates of any thereof.
Further features ofthe invention include:
(i) A compound of formula (IA) or a physiologically functional derivative thereof or a solvate of any thereof for use in the treatment or prophylaxis of restenosis.
(ii) The use of compounds of formula (IA) or a physiologically functional derivative thereof or a solvate of any thereof in the manufacture of a medicament for the prevention or treatment of restenosis.
As used herein, the term "alkyl" as a group or part of a group means a straight or
branched chain alkyl group. Such alkyl groups preferably have from 1 to 3 carbon atoms. As used herein, the term "aryl" as a group or part of a group includes phenyl, pyridyl, naphthyl, pyrrolo, thienyl, furyl, the term heteroaryl includes a 5- or 6- membered ring where from 1 to 3 atom(s) are selected from N, O, and S, optionally fused to an aryl ring (for example quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, benzothienyl, benzoxazolyl, benzothiazolyl, etc.), and the term heterocycle includes a 5- or 6- membered ring where from 1 to 3 carbon atom(s) are replaced by atom(s) selected from N, O, and S (for example morpholine, pyrrolidine, piperidine, piperazine) which may be partially or completely saturated.
Preferred esters in accordance with the invention include carboxylic acid esters in which the non-carbonyl moiety ofthe carboxylic acid portion ofthe ester grouping is selected from straight or branched chain alkyl (for example, methyl, n-propyl, t-butyl, or n- butyl), cycloalkyl, alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted by, for example, halogen, Cj_4 alkyl, or Cj_4 alkoxy), or amino; sulphonate esters, such as alkyl- or aralkylsulphonyl (for example, methanesulphonyl); amino acid esters (for example, L-valyl or L-isoleucyl); and mono-, di-, or tri-phosphate esters. In such esters, unless otherwise specified, any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms. Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group. Any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salt thereof and to a solvate of any thereof.
Examples of pharmaceutically acceptable salts of the compounds of formula (I) and physiologically functional derivatives thereof include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and X4+ (wherein X is
salts derived from an appropriate acid, for example, organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids, organic sulphonic acids, such as methanesulphonic, ethanesulphonic, benzenesulphonic and p-toluenesulphonic acids, and inorganic acids, such as hydrochloric, sulphuric, phosphoric and sulphamic acids.
As used herein, the term "physiologically functional derivative" means a chemical derivative, for example a physiologically acceptable salt, ester, or salt of such ester, of a compound of formula (I) or (IA) which has the same physiological function as the free compound of formula (I) or (IA), for example, by being convertible in the body to the free compound of formula (I) or (IA) or an active metabolite or residue thereof.
The present invention further includes a method for the treatment of a mammal, such as a human, to prevent or alleviate restenosis, for example, restenosis following angioplasty which comprises the adrrjinistration of a therapeutically effective amount of a compound of formula (I) or (IA) or a physiologically functional derivative thereof or a solvate of any thereof.
For brevity, the term "a compound of the invention" is used hereinafter to describe a compound of formula (I) or (IA) or any of its physiologically functional derivatives, or solvates of any thereof.
The amount of a compound of the invention required to achieve a therapeutic effect will, of course, vary with the specific compound chosen, the route of administration, the subject under treatment, and the particular condition which is to be prevented. A suitable daily dose for a mammal is in the range 0.5 to 120mg of compound/kilogram bodyweight, the preferred daily dosage being 2 to 60mg kg, which may be administered as two or more sub-doses daily.
While it is possible for a compound of the invention to be administered alone, it is preferable to present it as a pharmaceutical formulation comprising the compound of the invention in association with a pharmaceutically acceptable carrier or excipient and, optionally, one or more other therapeutic ingredients. The present invention, therefore, also provides pharmaceutical formulations for use in the prophylaxis or treatment of restenosis, for example, restenosis following angioplasty containing a compound of formula (I) or (IA) or a physiologically functional derivative thereof or a solvate of any thereof, at least one pharmaceutical carrier or excipient and, optionally, one or more other therapeutic ingredients.
The pharmaceutical carrier or excipient must, of course, be compatible with the other ingredients in the formulation and must not be detrimental to the patient. The active
ingredient may comprise from 0.1% to 99.9% by weight of the formulation. Typical unit doses of a pharmaceutical formulation according to the invention contain from 1 to 1500mg and preferably from 10 to 700mg ofthe active ingredient.
Pharmaceutical formulations according to the invention may be adapted for administration by oral or parenteral (including intravenous, intradermal or intramuscular) routes, or may also be administered during the surgical procedure via an angioplasty cannula (for example, a l-50mg dose); by this means the formulated drug is introduced at the site of the angioplasty through perforations in the balloon catheter used to open up the atherosclerotic stenosis. In a further mode of administration, the resulting restenosis may be 'held open' by means of a tubular stent which may be impregnated with a compound of the invention which gradually leaches into the site of the angioplasty.
Pharmaceutical formulations of the invention may conveniently be presented in unit dosage form and may be prepared by any method known in the art of pharmacy. Such methods include the step of bringing the active ingredient into association with a carrier or excipient and, optionally, containing one or more accessory ingredients. In general, pharmaceutical formulations are prepared by uniformly and ultimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier, or both, and then, if desired, shaping the product into the required form.
Pharmaceutical formulations adapted for oral administration may be in the form of discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount ofthe active ingredient; in the form of a powder or granules; in the form of a solution or suspension in an aqueous or non-aqueous liquid; edible foams or whips; or in the form of an oil-in-water or water-in-oil emulsion. The formulation may also be in the form of a bolus, electuary, or paste.
A tablet may be made by compressing or moulding the active ingredient, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent and/or surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active ingredient and a suitable carrier or
excipient moistened with an inert liquid diluent.
Pharmaceutical formulations adapted for parenteral administration typically comprise a sterile aqueous or non-aqueous preparation of the active ingredient (where necessary, solubilised in a small amount of an appropriate organic solvent) which may contain anti¬ oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the patient. Such formulations may also be in the form of aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition ofthe sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
Pharmaceutical formulations suitable for administration via an angjoplasty cannula are typically the same as those used for intravenous administration.
In addition to the aforementioned ingredients, the formulations may include one or more additional ingredients conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
The compounds of the invention may be prepared by one or more of the methods described in WO 93/18766, WO 93/24491, and pending WO 95/07910 which are incorporated herein by reference.
Example 1
Preparation of 3 -(1 -Cn-propyD- lH-indol-3 -ylV4-( lH-indol-3 -vD- 1 -methyl- 2T 5-dihydro- lH-pyrτolo-2.5-dione
To a solution of 3,4-bis-(lH-indol-3-yl)-l-me1iιyl-2,5-dihydro-l-H-pyrτolo-2,5-dione (2.14g, 6.27mmol) in DMF (30ml) was added NaH (80%, 280mg). After 20 minutes at room temperature, propyl iodide (0.7ml) was added and the mixture stirred overnight at room temperature. The mixture was quenched by the addition of acetic acid (2ml),
evaporated in vacuo and chromatographed over flash silica, eluting with hexane/ethyl acetate (3:1), (2: 1) and (1:1). Pooling and evaporation of the appropriate fractions afforded the title compound as a red solid. M.p. 159-160°C
The following compound was prepared by a similar method, replacing propyl iodide with 2-iodo- 1 , 1 , 1 -trifluoroethane.
Example IA
3-π-f2.2.2-Trifluoroeτhvn-lH-indol-3-vn-4-riH-indol-3-vn-l-methyl-2.5-dihvdro- 1 H-pyrrolo-2.5-dione
M.p. 247°C
Example 2
3 -( 1 -Ethyl-6-cvano- lH-indol-3-vn-4-( lH-indol-3-yl)- lH-pyrrolo-2.5-dione
Triethyloxonium tetrafluroborate (3.99g) was added to a suspension of indole-3- acetamide (3.48g, 20mmol) in dichloromethane (100ml) and the mixture warmed gently to effect dissolution. After stirring for 2 hours at room temperature, ethyldiisopropylamine (14ml) was added (solution A).
To a solution of 6-cyano-l-ethylindole (3.4g 20mmol) in dry dichloromethane (50ml) was added oxalyl chloride (1.74ml) and the solution stirred at room temperature for 3 hours. After evaporation of the solvent in vacuo. and co-evaporation with dry dichloromethane, the material was suspended in dry dichloromethane (100ml) and added dropwise to solution A at room temperature and stirred for 24 hours.
Aqueous 10% sodium bicarbonate solution (80ml) was added, the organic layer separated, dried (Na2SO4) and evaporated until all of the solvent had been removed. The resulting orange foam was taken up in a mixture of dichloromethane (70ml) and toluene (35ml), and p-toluenesulphonic acid monohydrate (4.2g) added. After stirring overnight at room temperature, the red mixture was washed with 10% sodium
bicarbonate solution, separated, dried (Na2SO_j,) and evaporated. Purification by flash chromatography over silica, eluting with hexane/ethyl acetate (3:1), (2:1) and (1:1), followed by recrystallisation from ethyl acetate (1:1), gave the title compound as red crystals.
M.p. 183-184°C
Example 3
General Method for the Preparation of 3.4-Bis-πH-indol-3-yl) maleic anhydrides
A solution ofthe 3,4-bis(l-H-indol-3-yl)-2,5-dihydro-l-methyl-lH-pyrrolo-2,5-dione in 10% aqueous potassium hydroxide and a co-solvent, preferably dioxane or methanol, was heated under reflux for 1-30 hours. When TLC analysis (Siθ2) revealed the absence of starting material, the mixture was cooled and acidified. If the product precipitated at this stage, it could be isolated by filtration and optionally crystallised. Alternatively, the product could be extracted, for example with ethyl acetate, and then purified by crystallisation or column chromatography over silica. Often the product could be used directly in the next step without purification.
The following examples where thus prepared.
Example 3 A
3-flH-jJιdol-3-vn-4-π-f2.2.2-trifluoromethvn-lH-indol-3-vnmaleic anhydride
After acidification, extraction and evaporation, this was used directly in the next step.
Example 3B
3 -( 1 H-Indol-3 -yTι-4-( 1 -(n-propyP- 1 H-indol-3-yDmaleic anhydride
After acidification, extraction and evaporation, this was used directly in the next step.
Example 4
Preparation of 3 -f 1 -Ethyl-6-nitro- 1 H-indol-3 -vϊ)-4-( 1 -(p-toluene sulphonylV 1H- indol-3-v0maleic anhydride
To a solution of l-ethyl-6-nitroindole (2.3g, 12mmol) in dry dichloromethane (50ml) was added oxalyl chloride (3 ml, 3eq) and the solution stirred at room temperature for 3 hours. The solvent was removed in vacuo. co-evaporated with dry dichloromethane, and suspended in dry dichloromethane (120ml). This was added slowly to a mixture of 1 -p-toluene sulphonyl indole 3-acetic acid (4g, 12mmol) and ethyldiisopropylamine (2.2ml, 2eq) in dichloromethane (30ml) and the mixture stirred overnight at room temperature. A further 1.1ml ethyl diisopropylamine was added and the mixture stirred for a further 2 days. The mixture was washed with aqueous sodium bicarbonate solution (10%), the organic layer separated, dried (Na2SO4) and evaporated. Chromatography over flash silica eluting with hexane/ethyl acetate (10:1), then (4:1), 2:1), (1 : 1) and finally (1:2) gave the product as a bright yellow solid.
Example 5
Preparation of 3-0 -Ethyl-6-nitro-lH-indol-3-vπ-4-(lH-indol-3-yl maleic anhydride
Example 2 (2.3g) in methanolic potassium hydroxide solution (0.1M, 400ml) was heated under reflux for 9.5 hours. The methanol was evaporated in vacuo. HC1 (2N, 200ml) added to give a solution of pH 1-2, the mixture extracted with ethyl acetate (300ml), the organic layer separated, washed with brine and dried (Na2SO4). Evaporation afforded the product as a red solid.
Example 6
General Method for the Preparation of 3.4-bis-f lH-indol-3-ylV2.5-dihvdro- lH-pyrτolo-2.5-diones from 3.4-bis ( lH-indol-3-vD maleic anhydrides
A mixture ofthe 3,4-bis(lH-indole-3-yl) maleic anhydride and an excess of ammonium acetate (typically 10-250 equivalents) were heated at 140°C until reaction was complete (typically 15-240 minutes). The mixture was then cooled, partitioned between ethyl
acetate and water (brine, aqueous HCl or bicarbonate solution may be used), and the organic phase separated. After further washings, the organic phase is dried (MgSO4) and evaporated. The product may then be recrystallised or purified by flash chromatography over silica. The following examples were thus prepared.
Example 6A
3-riH-mdol-3-yl -r -f2.2.2-trifluoromethvn-lH-indol-3-vn-2.5-dihvdro-lH- pyrrolo-2.5-dione
M.p. 238°C
Example 6B
3-riH-jjdol-3-vn-4-fl-(n-propyn-lH-indol-3-vn-2.5-dihvdro-lH-pyrrolo-2.5-dione
M.p. 172-173°C
Example 6C]
3-ri-Ethyl-6-mtro-lH-indol-3-vn-4-nH-indol-3-vn-2-5-dihvdro-lH-pyrrolo- 2.5-dipne
Mp. 272-273°C
Example 7
General methods for the preparation of 12.13-Dihvdro-5H-indolor2.3al-pyrrolo [3.4c]carbazole-5.7/'6ID-diones
a) To a solution of the 3,4-Bis(lH-indol-3-yl)-2,5-dihydro-lH-ρyrrolo-2,5-dione derivative in xylene, toluene, or dioxane, or combinations thereof at 100-140°C was added 2,3-dichloro-5,6-dicyanobenxoquinone (1.1 equivalents) and r>- toluenesulphonic acid (0.01-1.2 equivalents). The mixture was maintained at this temperature until TLC monitoring indicated that the reaction was complete
(usually 1-60 minutes). The mixture was then cooled. If the product precipitated, it was isolated by filtration and recrystallisation. Otherwise sodium bicarbonate solution was added and the organic layer separated, dried (Na2SO4) and evaporated. Some examples can be purified by recrystallisation at this stage. Otherwise the products were purified by flash chromatography over silica or basic alumina (eluted with hexane, ethyl acetate, acetone, THF, or combinations thereof).
b) A solution of the 3,4-bis(lH-indol-3-yl)-2,5-dihydro-lH-pyrrolo-2,5-dione in a suitable solvent (preferably isopropanol) containing iodine (1.2eq) was irradiated (λ, 254-350nM) for 1-7 days whilst oxygen or preferably nitrogen was bubbled through the solution. If the product precipitated it was isolated by filtration and crystallised from a suitable solvent (ethyl acetate, acetone, DMF, DMSO). If not, the solvent was evaporated in vacuo. the residue taken up in ethyl acetate and washed successively with sodium thiosulphate solution and sodium bicarbonate solution, separated, dried (Na2SO4), evaporated and the product purified by crystallisation or flash chromatography over silica. The following compounds were thus prepared.
Example 7A
12-Ethyl- 12.13-dihvdro- 10-cvano-5H-indolor2.3a1pyrrolor3.4c1carbazole-5.7r6H)- dione
Mp. >300°C
Example 7B
12-Propyl-12.13-dihvdro-5H-indolor2.3a1pyrrolor3.4c1carbazole-5.7('6 r)-dione
M.p. >335°C
Example 7C
12-f 2.2.2-Trifluoroethvn- 12.13-dihvdro-5H-indolo[2.3 a]pyrrolor3 ,4c1carbazole- 5.7r6HVdione
M.p. >330°C
Example 7D
12-Ethyl-12.13-dihvdro-10-nitro-5H-indolo[2.3a1pyrrolor3.4c1carbazole- 5.7f6HVdione
M.p. >300°C
Example 8
Preparation of 13-ethyl-12.13-dihvdro-2-carboxy-5H-indolo[2.3a]pyττolo["3.4c]- carbazole-5.1( 6H)-dione
A mixture of 7 A (118mg) in dioxan (20ml) and sodium hydroxide (20ml, 8N) was heated under reflux for 9 hours with vigorous stirring. Acidification with cone. HCl formed a yellow precipitate. Ethyl acetate (60ml), dioxan (30ml) and water (50ml) were added and the yellow-green organic layer separated. The aqueous layer was washed with ethyl acetate, the organic layers combined, dried (Na2SO4) and evaporated to dryness. The residue was taken up in DMF (10ml), HMDS (3ml) and methanol (3ml) were added and the solution stirred overnight at room temperature. Ethanol (2ml) was added and the solvent removed jn vacuo. Recrystallisation from hexane/ethyl acetate gave the title compound as an orange solid. M.p. >300°C.
Example 9
Preparation of 13-emyl-12.13-ά ιvαVo-2-anιino-5H-indolor2.3a1ρvιτolor3.4c1 carbazole-5.7(6H)-dione
A solution of (180mg) and 10% Pd/C (lOOmg) in DMF (100ml) was hydrogenated at 50 atmospheres for 18 hours. The mixture was filtered through hyflo, the filtrate
evaporated and chromatographed over flash silica, eluting with ethyl acetate containing 1% triethylamine. Pooling and evaporation of the appropriate fractions afforded the title compound as an orange solid, after recrystallisation from dimethyl sulphoxide. M.p. >300°C
Example 10
Preparation of 12.13-Dihydro-3.9-dihvdroxy-5H-indolor2.3alpyrrolor3.4c1carbazole- 5.7f6HVdione
A mixture of 12,13-d^ydro-3,9-dimethoxy-5H-indolo[2,3a]pyrτolo[3,4c]carbazole- 5,7(6H)-dione (66mg) and pyridine hydrochloride (800mg) was heated to 180°C in a sealed tube and maintained at 180°C for one hour. Water and ethyl acetate were added, the organic layer washed with dilute HCl, then brine, dried (MgSO4) and evaporated. The residue was purified by flash chromatography over silica, eluting with hexane/ethyl acetate (4:1). Pooling and evaporation of the appropriate fractions afforded the product as an orange solid. Mass spec (El): 357 (M+) M.p. >300°C
Example 11
Preparation of 12-(3-Acetoxypropyl 2.13-dihvdro-6-methyl-5H-indolor2.3a1pyrτolo 3.4clcarbazole-5.7f6Hι-dione
To a solution of 3,4-bis-(lH-indol-3-yl)-2,5-dihydro-l-methyl-lH-pyrrolo-2,5-dione (3.41g, lOmmol) in dry DMF (30ml) under nitrogen at 0°C was added NaH (60% in mineral oil, 440mg, l lmmol) and the mixture stirred at room temperature for 30 minutes. The mixture was cooled to -10°C and 3-chloropropylacetate (1.36g, lOmmol) added. The mixture was stirred overnight at room temperature, then evaporated to dryness, taken up in EtOAc and washed with brine. The organic fraction was dried (Na2SO4), evaporated and chromatographed over flash silica. Elution with hexane/EtOAc (5:2) gave 3-(l-(3-acetoxypropyl)-lH-indol-3-yl)-4-(lH-indol-3-yl)-2,5- dihydro-l-methyl-lH-pyrrolo-2,5-dione as a red solid.
Cycylisation was effected according to the method described in 7a), using toluene as the solvent. Chromatography over silica, eluting with hexane/EtOAc (1 :1) gave the title compound (11) as a yellow-green powder. M.p. 237-240°C
Example 12
Preparation of 12-(3-HvdroxypropyD12.13-dihydro-5H-indolof2.3alpyrrolo r3.4c]carbazole-5.7 6H,-dione
A solution of 11 (509mg) in dioxan (40ml) and 10% KOH solution (100ml) was stirred at room temperature for 2 days. The mixture was neutralised with aqueous HCl and extracted with ethyl acetate. Chromatography over flash silica eluting with EtOAc/hexane (1:1), then (2:1), gave the cyclic anhydride. A mixture of the cyclic anhydride (387mg) and ammonium acetate (3.85g) was heated at 140°C for 2 hours. After cooling, the mixture was diluted with water and extracted twice with ethyl acetate. The combined organic extracts were dried (MgSO4), evaporated and fractionated over flash silica, eluting with hexane/EtOAc (1:2) to give the title compound as a golden-yellow powder. M.p. ~350°C (dec)
C23H17N3θ3.0.2CH3Cθ2Et requires C, 71.29%; H, 4.64%; N, 10.48%
Found C, 71.48%; H, 4.48%; N, 10.29%
Example 13
Preparation of I2-f2.3-Dihvdroxybutyl'ιl2.13-dihvdro-5H-indolor2.3a1pyrrolo f 3.4c]carbazole-5.1( 6H)-dione
To a suspension of 12,13-dihydro-6-methyl-5H-indolo[2,3a]pyrrolo[3,4c]carbazole- 5,7(6H)-dione (204mg, 0.6mmol) in dry DMF (10ml) was added 60% NaH (28.8mg, 0.72mmol) under nitrogen and the mixture stirred at room temperature for 30 minutes. Crotyl chloride (58.5μL, leq) was added and the mixture stirred at room temperature overnight. The mixture was partitioned by the addition of aqueous HCl and EtOAc, the
organic layer separated, dried (MgSO4), evaporated and chromatographed over flash silica. Elution with hexane/EtOAc (2:1), then (3:2), gave 12-(but-2-ene), 13-dihydro-6- methyl-5H-mdolo[2,3a]pyrrolo[3,4c]carbazole-5,7(6H)-dione (13A).
A solution of 13 A (l lδmg, 0.3mmol) in dioxan (5ml) and 10% KOH solution (5ml) was heated under reflux for 18 hours. The mixture was partitioned by the addition of aqueous HCl and EtOAc, the organic layer separated, dried (MgSO4), evaporated and purified by flash chromatography over silica, eluting with hexane/EtOAc (2:1), (1:1), then EtOAc, affording the cyclic anhydride (13B).
A solution of 13B (49.4mg) in DMF (3ml), HMDS (273μL) and MeOH (25.7μL) was stirred overnight at room temperature. A further 140μL HMDS and 13uL MeOH was added and stirring continued for 2 days. Aqueous HCl was added, and the resulting precipitate filtered off. This was purified by flash chromatography over silica, eluting with hexane/EtOAc (2:1), (3:2), and finally (1:1), to afford 12-(but-2-ene), 13-dihydrc- 5H-indolo[2,3a]pyrrolo[3,4c]carbazole-5,7(6H)-dione (13C).
To a solution of 13C (30mg, 0.08mmol) in acetone (6ml) was added N-methyl morpholine N-oxide (23.1mg, O.l lmmol) followed by osmium tetroxide (1 crystal) and one drop of water. The mixture was stirred overnight at room temperature, diluted with acetone, absorbed onto flash silica and purified by flash chromatography over silica, eluting with EtOAc/hexane (3:1). This afforded the title compound (13) as a yellow powder. M.p. 285-288°C
Anal. C24H19N3θ4.0.5H2O requires C, 68.25%; H, 4.74%; H, 9.95%
Found C, 68.27%; H, 4.55%; N, 9.78%
PHARMACEUTICAL FORMULATION EXAMPLE
The "active ingredient" in the following formulation example is a compound of the invention as defined above.
Liposome dispersion
Ingredients Ouantitv
Active ingredient lOOmg
Dipalmitoyl phosphatidylcholine 25.1mg
Cholesterol 13.0mg
Phosphatidylserine 3.8mg
Sodium chloride 9.0mg
Water for injection to make 1ml
BIOLOGICAL DATA
PDGFr Autoohosohorvlati ion Assay
Confluent monolayers of rat aortic smooth muscle cells (AlO) were incubated in Dulbecco's Modified Eagles Media (DMEM) plus 0.2% foetal calf serum for 24hrs. After this period the cells were stimulated with PDGF in the presence or absence of inhibitor. The assay was terminated by harvesting the cells on ice in a lysis buffer. (5mM Tris pH8.0, 1% NP40, 150mM NaCl). The cell lysates were prepared for polyacrylamide gel electrophoresis by boiling with sodium dodecylsulphate (SDS) sample buffer (0.3125M Tris pH 6.8, 10% SDS, 50% glycerol 5mM dithiothreitol (DTT)) and separated using a discontinuous polyacrylamide gel electrophoresis system as described in Nature, 227, 680 (1970), Laemelli.
The separated phosphorylated proteins were transferred onto nitrocellulose membrane (Scheicher and Schuell. Anderman Kingston, Surrey) using an eletrophoretic Western blotting technique based on a method described in Anal. Biochem., 112. 195, (1981),Burnette.
The phosphotyrosine proteins were detected immunocytochemically using a mouse anti- phosphotyrosine monoclonal 4G10 (UBI Lake Placid, NY) followed by a second sheep anti-mouse IgG monoclonal with a radioiodinated label (Amersham Int., Little Chalfont, Bucks). The proteins were then visualised and quantitated using a Phospholmager™ (Molecular Dynamics Sevenoaks, Kent).
When tested in this assay, representative compounds of the invention were found to significantly inhibit PDGFr tyrosine kinase at a concentration of lμM. In particular, 12-(2,3-dihydroxy- 1 -propyl)-l 2, 13-dihydro-5H-indolo[2,3-a]pytτolo- [3,4-c]-carbazole-5,7(6H)dione and 12,13-dihydro-3,9-dimethoxy-5H-indolo[2,3-a]- pyrrolo[3,4-c]-carbazole-5,7(6H)dione were each found to have an IC50 of less than 50nM
Claims
1. Use of compounds of formula (I)
wherein:
R! and R2 are independently selected from:
-H,
-OR6, -COR6, -CO2R6 where R6 is Cι.g alkyl, C3.7 cycloalkyl, aryl (for example phenyl), arylalkyl (for example benzyl), C2-6 alkenyl, or H,
-NR7R8 where R7 and R8 are independently selected from H, -COR6 (where R6 is as defined above), C^galkyl, C3_7cycloalkyl, aryl, and arylalkyl, or R7 and R8 together with the N atom to which they are attached form a 3-, 4-, 5- or 6- membered heterocyclic ring (for example piperidine, pyrrolidine) in which from 1 to 3 ofthe carbon atoms are replaced by heteroatoms independently selected from O, N and S (for example, morpholino, piperazine) which ring may where possible be partially or completely unsaturated, and
-Cj^alkyl, C2-4alkenyl, C3_8cycloalkyl, where the alkyl, alkenyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from: halogen, cyano, nitro, azido, -OR6, -SR6, -SO2R6 (where R6 is as defined above),
-NR7R8, -T-C(Z)-NR7R8 (where T is NH or S, Z is NH, S or O and R7and
R8 are as defined above), heterocycle, -NH-heterocycle, heteroaryl, and aryl (for example phenyl, pyridyl, furyl, thienyl, pyrrole, naphthyl) optionally substituted by one or more substituents selected from -OR6, -NR7R8, -SR6, -SO2R6, -CO2R6, nitro, cyano, SCN, C^galkyl, C3_6cycloalkyl, haloalkyl (for example trifluoromethyl), hydroxylalkyl, -CONH2, halogen and methylenedioxy, (where
R6,R7, and R8 are each as defined above);
R3 is selected from:
-H,
-COR6, -CH2OR6, -CO2R6, -OR6 (where R6 is as defined above),
-NR7R8, and -CH2NR7R8 (where R7 and R8 are as defined above);
R4 and R-> either together with the carbon atom to which they are attached form a carbonyl group (>=O) or R4 is H and R5 is selected from H, -OR6,and -SR6, (where R6 is as defined above);
A and B, which may be the same or different, together with the carbon atoms to which they are attached each represent a phenyl ring in which from 1 to 3 carbon atom(s) may be replaced by nitrogen atom(s), the nitrogen atom(s) being optionally substituted with an oxide group;
A and B are optionally substituted by one or more ring substituent(s) selected from:
-Cμgalkyl optionally substituted by -OR6 (where R6 is as defined above), halogen (for example trifluoromethyl), or -NR R8 (where R7 and R8 are as defined above),
cyano, nitro, halogen, methylenedioxy, -OR6, -SR6, -SOR6, -SO2R6, -CO2R6 -NHCOR6 (where R6 is as defined above),
-SO2NR7R8, -NHSO2R8, -CONR7R8, and -NR7R8 (where R7 and R8 are as defined above);
provided that when A and B together with the carbon atoms to which they are attached both represent a phenyl ring R3 is not -CH2OR6 or -CH2NR7R8 and rings A and B are not substituted by -NHCOR6, (where R6, R7, and R8 are as defined above);
or a physiologically functional derivative thereof or a solvate of any thereof in the manufacture of a medicament for the treatment or prophylaxis of restenosis.
2. Use according to claim 1 of a compound of formula (I) selected from:
12-(2,3 -Dihydroxy- 1 -propyl)- 12, 13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4- cjcarbazole -5,7(6H)-dione;
12,13-Dihydro-3,9-dimethoxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione;
12, 13-Dilτydro-3,9-dihydroxy-5H-indolo[2,3-a]ρyrrolo[3,4-c]carbazole- 5,7(6H)-dione;
13-Ethyl-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)- dione;
12-(3-Aminopropyl)-12,13-dihydro-5H-mdolo[2,3-a]pyrτolo[3,4-c]carbazole- 5,7(6H)-dione;
13H-12-Ethylpyrido[2 3 2,3]pyπ•oIo[2,3-a]pyπ•olo[3,4-c]carbazole-5,7(6H)- dione; 12,13-Dihydro-pyrido[2,,3':2,3]pyrrolo[3,4-c]carbazole-5,7(6H)-dione; and
12-(3-Propanamide)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione;
and physiologically functional derivatives thereof and solvates of any thereof for use in the manu&cture of a medicament for the prophylaxis or treatment of restenosis.
A compound of formula (IA) wherein:
R! is H and R2 is selected from: -OR6', -CO2R6' where R6' is Ci^alkyl, C2-6alkenyl, or H, cyano,
where R7* is H and R8' is Ci^alk l -C2-4 lkyl optionally substituted with -OR6 where R6' is as defined above;
R3 is H;
R4 and R^ together with the carbon atom to which they are attached form a carbonyl group (>= ));
A and B together with the carbon atoms to which they are attached each represent a phenyl ring substituted by one or more ring substituent(s) selected from:
-OR6', -CO2R6' (where R6' is as defined above), cyano,
-Cι_4alkyl optionally substituted with -OR6' (where R6' is as defined above), and
-NR7"R8" where R7" and R8" are indepenently selected from H or
C^alkyl;
provided that when A and B are both unsubstituted phenyl rings R2 is not ethyl or 2,3-dihydroxypropyl;
or a physiologically functional derivative thereof or a solvate of any thereof.
4. A compound of formula (IA) according to claim 3 selected from:
12-Ethyl-12, 13-dihydro-l 0-amino-5H-indolo[2,3a]pyrrolo[3,4c]carbazole- 5,7(6H)-dione;
12-Ethyl- 12, 13-dihydro- 10-carboxy-5H-indolo[2,3a]pyrrolo[3,4c]carbazole- 5,7(6H)-dione;
12-Propyl-12,13-djJiydro-5H-indolo[2,3a]pyrrolo[3,4c]carbazole-5,7(6H)- dione;
12-(2,2,2-Trjfluoroethyl)-12,13-dihydro-5H-indolo[2,3a]ρyrrolo[3,4c] carbazole-5,7(6H)-dione;
12-(3-Hydroxypropyl)-12,13-dϋιydro-5H-indolo[2,3a]pyrrolo[3,4c] carbazole-5, 7(6H)-dione;
12-(2,3-Dihydroxybutyl)-12,13-dihydro-5H-indolo[2,3a]pyrrolo[3,4c] carbazole-5,7(6H)-dione; and
12-(13-Acetoxypropyl)12,13-dfljydro-5H-indolo[2,3a]pyrrolo[3,4c]carbazole- 5,7(6H)-dione; and physiologically functional derivatives thereof and solvates of any thereof.
5. A compound of formula (IA) as claimed in either Claim 3 or 4 for use in the treatment or prophylaxis of restenosis.
6. A method for the treatment of a mammal to prevent or alleviate restenosis, which comprises the administration of a therapeutically effective amount of a compound of formula (I) or (IA) according to any claim from 1 to 3, or physiologically functional derivative thereof or a solvate of any thereof.
7. A pharmaceutical formulation comprising of a compound of formula (IA) as defined in claim 3, or a physiologically functional derivative thereoζ or a solvate of any thereof, and at least one pharmaceutical carrier or excipient and, optionally, one or more other therapeutic ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU31875/95A AU3187595A (en) | 1994-08-13 | 1995-08-11 | Compounds for the treatment of restenosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9416467A GB9416467D0 (en) | 1994-08-13 | 1994-08-13 | Compounds for use in medicine |
| GB9416467.0 | 1994-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996004906A1 true WO1996004906A1 (en) | 1996-02-22 |
Family
ID=10759889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1995/001899 WO1996004906A1 (en) | 1994-08-13 | 1995-08-11 | Compounds for the treatment of restenosis |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3187595A (en) |
| GB (1) | GB9416467D0 (en) |
| WO (1) | WO1996004906A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| FR2826653A1 (en) * | 2001-06-29 | 2003-01-03 | Servier Lab | NOVEL PYRIDO-PYRIDO-PYRROLO [3,2-G] PYRROLO [3,4-E] -INDOLE AND PYRIDO-PYRROLO [2,3-A] PYRROLO [3,4-C] CARBAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| JP2003507480A (en) * | 1999-08-20 | 2003-02-25 | セフアロン・インコーポレーテツド | Isomeric fused pyrrolocarbazoles and isoindolones |
| WO2003027275A1 (en) | 2001-09-27 | 2003-04-03 | Alcon, Inc. | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| ES2189597A1 (en) * | 2000-07-18 | 2003-07-01 | Fundacion Universitaria San Pablo-Ceu | Set of anti cancer agents consists of dione derivatives synthesised from an e.g. monosubstituted anhydride for amine and pharmaceutical production |
| DE10161940A1 (en) * | 2001-12-17 | 2003-07-03 | Nad Ag | N-carbacycle-monosubstituted indolocarbazoles as protein kinase inhibitors |
| US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
| US7202266B2 (en) * | 2003-07-17 | 2007-04-10 | Plexxikon, Inc. | PPAR active compounds |
| US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| US7531568B2 (en) | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
| US8053463B2 (en) | 2007-03-08 | 2011-11-08 | Plexxikon Inc. | PPAR active compounds |
| WO2016008966A1 (en) | 2014-07-17 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018766A1 (en) * | 1992-03-20 | 1993-09-30 | The Wellcome Foundation Limited | Further indole derivatives with antiviral activity |
-
1994
- 1994-08-13 GB GB9416467A patent/GB9416467D0/en active Pending
-
1995
- 1995-08-11 AU AU31875/95A patent/AU3187595A/en not_active Abandoned
- 1995-08-11 WO PCT/GB1995/001899 patent/WO1996004906A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018766A1 (en) * | 1992-03-20 | 1993-09-30 | The Wellcome Foundation Limited | Further indole derivatives with antiviral activity |
Non-Patent Citations (4)
| Title |
|---|
| BIOCHEM. PHARMACOL., vol. 39, no. 5, pages 968 - 972 * |
| CHEMICAL ABSTRACTS, vol. 107, no. 3, Columbus, Ohio, US; abstract no. 17329q, H. NAKANO ET AL.: "Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein" page 27; * |
| CHEMICAL ABSTRACTS, vol. 112, no. 21, Columbus, Ohio, US; abstract no. 191499h, R. OLSEN ET AL.: "Staurosporine inhibition of intracellular free calcium transients in mitogen-stimulated Swiss 3T3 fibroblasts" page 31; * |
| J. ANTIBIOT., vol. 40, no. 5, pages 706 - 708 * |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003507480A (en) * | 1999-08-20 | 2003-02-25 | セフアロン・インコーポレーテツド | Isomeric fused pyrrolocarbazoles and isoindolones |
| JP4776842B2 (en) * | 1999-08-20 | 2011-09-21 | セフアロン・インコーポレーテツド | Isomeric condensed pyrrolocarbazoles and isoindolones |
| US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| ES2189597A1 (en) * | 2000-07-18 | 2003-07-01 | Fundacion Universitaria San Pablo-Ceu | Set of anti cancer agents consists of dione derivatives synthesised from an e.g. monosubstituted anhydride for amine and pharmaceutical production |
| US7001906B2 (en) | 2001-06-29 | 2006-02-21 | Les Laboratoires Servier | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| FR2826653A1 (en) * | 2001-06-29 | 2003-01-03 | Servier Lab | NOVEL PYRIDO-PYRIDO-PYRROLO [3,2-G] PYRROLO [3,4-E] -INDOLE AND PYRIDO-PYRROLO [2,3-A] PYRROLO [3,4-C] CARBAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| WO2003002563A1 (en) * | 2001-06-29 | 2003-01-09 | Les Laboratoires Servier | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| US7598288B2 (en) | 2001-09-27 | 2009-10-06 | Alcon, Inc. | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| WO2003027275A1 (en) | 2001-09-27 | 2003-04-03 | Alcon, Inc. | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| EP2281560A1 (en) | 2001-09-27 | 2011-02-09 | Alcon, Inc. | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy |
| US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
| DE10161940A1 (en) * | 2001-12-17 | 2003-07-03 | Nad Ag | N-carbacycle-monosubstituted indolocarbazoles as protein kinase inhibitors |
| US7262215B2 (en) | 2001-12-17 | 2007-08-28 | Nad Ag | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors |
| US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| US7491831B2 (en) | 2003-07-17 | 2009-02-17 | Plexxikon, Inc. | PPAR active compounds |
| US7723374B2 (en) | 2003-07-17 | 2010-05-25 | Plexxikon, Inc. | PPAR active compounds |
| US7476746B2 (en) | 2003-07-17 | 2009-01-13 | Plexxikon, Inc. | PPAR active compounds |
| US7202266B2 (en) * | 2003-07-17 | 2007-04-10 | Plexxikon, Inc. | PPAR active compounds |
| US8367828B2 (en) | 2003-07-17 | 2013-02-05 | Plexxikon Inc. | PPAR active compounds |
| US7531568B2 (en) | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
| US8053463B2 (en) | 2007-03-08 | 2011-11-08 | Plexxikon Inc. | PPAR active compounds |
| WO2016008966A1 (en) | 2014-07-17 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3187595A (en) | 1996-03-07 |
| GB9416467D0 (en) | 1994-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100830859B1 (en) | Imidazopyridine derivatives and pharmaceutical composition comprising the same | |
| CN101242839B (en) | Azaindazole compounds and methods of use | |
| RU2453548C2 (en) | Azaindoles useful as janus kinase inhibitors | |
| ES2401192T3 (en) | Deazapurines useful as inhibitors of janus kinases | |
| CA2744498C (en) | Mlk inhibitors and methods of use | |
| EP3651768B1 (en) | Heterocyclic inhibitors of atr kinase | |
| EP3668839B1 (en) | Heterocyclic inhibitors of atr kinase | |
| KR20090018895A (en) | Deazapurines useful as inhibitors of janus kinases | |
| EP3521288A1 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity | |
| JP5587206B2 (en) | Pyrazolo [1,5-a] pyrimidines useful as JAK2 inhibitors | |
| CN106220635B (en) | The dihydro diaza * and carbazole ketone at the condensed Fourth Ring or five rings as PARP inhibitor | |
| WO1996004906A1 (en) | Compounds for the treatment of restenosis | |
| CN101379061A (en) | Inhibitors of E1 activating enzyme | |
| JPH11509535A (en) | Cyclic GMP-specific phosphodiesterase inhibitors | |
| JPH11509517A (en) | Chemical substances | |
| KR20000023635A (en) | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties | |
| CA3124678A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| JP2021518344A (en) | ATR Kinase Heterocyclic Inhibitor | |
| AU2441800A (en) | Immunosurpressive effects of pteridine derivatives | |
| CA3178129A1 (en) | Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators | |
| JP2004533448A (en) | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes | |
| JPH0269496A (en) | Imidazo (4, 5-b) pyridine derivative | |
| AU2018238996A1 (en) | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | |
| JP2002500658A (en) | 2-amino-7- (1-substituted-2-hydroxyethyl) -3,5-dihydropyrrolo [3,2-d] pyrimidin-4-one | |
| CN104804016A (en) | Tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |